These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30289818)

  • 1. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.
    McMillan J; Szlachetka A; Zhou T; Morsey B; Lamberty B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
    AIDS; 2019 Mar; 33(3):585-588. PubMed ID: 30289818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
    Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
    Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creation of a long-acting rilpivirine prodrug nanoformulation.
    Hilaire JR; Bade AN; Sillman B; Gautam N; Herskovitz J; Dyavar Shetty BL; Wojtkiewicz MS; Szlachetka A; Lamberty BG; Sravanam S; Fox HS; Alnouti Y; Dash PK; McMillan JM; Edagwa BJ; Gendelman HE
    J Control Release; 2019 Oct; 311-312():201-211. PubMed ID: 31491432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.
    McMillan J; Szlachetka A; Slack L; Sillman B; Lamberty B; Morsey B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.
    Andrews CD; Bernard LS; Poon AY; Mohri H; Gettie N; Spreen WR; Gettie A; Russell-Lodrigue K; Blanchard J; Hong Z; Ho DD; Markowitz M
    AIDS; 2017 Feb; 31(4):461-467. PubMed ID: 27902508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A year-long extended release nanoformulated cabotegravir prodrug.
    Kulkarni TA; Bade AN; Sillman B; Shetty BLD; Wojtkiewicz MS; Gautam N; Hilaire JR; Sravanam S; Szlachetka A; Lamberty BG; Morsey BM; Fox HS; Alnouti Y; McMillan JM; Mosley RL; Meza J; Domanico PL; Yue TY; Moore G; Edagwa BJ; Gendelman HE
    Nat Mater; 2020 Aug; 19(8):910-920. PubMed ID: 32341511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir.
    Gautam N; McMillan JM; Kumar D; Bade AN; Pan Q; Kulkarni TA; Li W; Sillman B; Smith NA; Shetty BLD; Szlachetka A; Edagwa BJ; Gendelman HE; Alnouti Y
    Nat Commun; 2021 Jun; 12(1):3453. PubMed ID: 34103484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
    Thoueille P; Saldanha SA; Schaller F; Choong E; Veuve F; Munting A; Cavassini M; Braun D; Günthard HF; Duran Ramirez JJ; Surial B; Furrer H; Rauch A; Ustero P; Calmy A; Stöckle M; Di Benedetto C; Bernasconi E; Schmid P; Marzolini C; Girardin FR; Buclin T; Decosterd LA; Guidi M;
    Clin Pharmacol Ther; 2024 Jun; 115(6):1450-1459. PubMed ID: 38519844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of a long-acting nanoformulated abacavir prodrug.
    Singh D; McMillan J; Hilaire J; Gautam N; Palandri D; Alnouti Y; Gendelman HE; Edagwa B
    Nanomedicine (Lond); 2016 Aug; 11(15):1913-27. PubMed ID: 27456759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.
    Pons-Faudoa FP; Sizovs A; Di Trani N; Paez-Mayorga J; Bruno G; Rhudy J; Manohar M; Gwenden K; Martini C; Chua CYX; Varchi G; Marzinke MA; Grattoni A
    J Control Release; 2019 Jul; 306():89-96. PubMed ID: 31136811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat.
    Jucker BM; Alsaid H; Rambo M; Lenhard SC; Hoang B; Xie F; Groseclose MR; Castellino S; Damian V; Bowers G; Gupta M
    J Control Release; 2017 Dec; 268():102-112. PubMed ID: 29042321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
    Reese MJ; Bowers GD; Humphreys JE; Gould EP; Ford SL; Webster LO; Polli JW
    Xenobiotica; 2016; 46(5):445-56. PubMed ID: 26340566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.
    Ford SL; Lou Y; Lewis N; Kostapanos M; D'Amico R; Spreen W; Patel P
    Antivir Ther; 2019; 24(4):301-308. PubMed ID: 30896438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects.
    Spreen W; Ford SL; Chen S; Wilfret D; Margolis D; Gould E; Piscitelli S
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):481-6. PubMed ID: 25140909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabotegravir and rilpivirine for the treatment of HIV.
    Rial-Crestelo D; Pinto-Martínez A; Pulido F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):393-404. PubMed ID: 32164474
    [No Abstract]   [Full Text] [Related]  

  • 16. In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
    Rajoli RKR; Back DJ; Rannard S; Meyers CF; Flexner C; Owen A; Siccardi M
    Clin Pharmacokinet; 2018 Feb; 57(2):255-266. PubMed ID: 28540638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine.
    Guo D; Zhou T; Araínga M; Palandri D; Gautam N; Bronich T; Alnouti Y; McMillan J; Edagwa B; Gendelman HE
    J Acquir Immune Defic Syndr; 2017 Mar; 74(3):e75-e83. PubMed ID: 27559685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabotegravir long-acting for HIV-1 prevention.
    Andrews CD; Heneine W
    Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.
    Kraft JC; McConnachie LA; Koehn J; Kinman L; Collins C; Shen DD; Collier AC; Ho RJ
    AIDS; 2017 Mar; 31(6):765-770. PubMed ID: 28099191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.